Aurinia Pharmaceuticals Inc.
AUPH Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$17.04
KIRA · Stoqly’s AI analyst, in plain words
- Aurinia Pharmaceuticals Inc. had $283M of revenue in fiscal 2025, up 20.4% on the year before. Over five years, revenue changed +41.4% a year on average.
- Its operating margin was 37.1%, up 39.1 pts: of every 100 in sales, about 37 is left after running the business.
- Aurinia Pharmaceuticals Inc. made $287M of net profit in fiscal 2025.
- Aurinia Pharmaceuticals Inc. returned $98.2M to shareholders in fiscal 2025. The diluted share count fell 5.1%.
Market cap
$2.3B
P/E
7.4x
Revenue
$283M
Net income
$287M
Free cash flow
—
Operating margin
37.1%
Aurinia Pharmaceuticals Inc. in 30 seconds · fiscal 2025
Are sales growing?
+20.4%
Yes. Sales grew 20.4% last year.
Does it make a profit?
101.5%
Yes. It keeps 101.5% of every sale as profit.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
7.4x
One share costs 7.4 times its yearly profit per share.
What Aurinia Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Aurinia Pharmaceuticals Inc.
- CIK
- 0001600620
Aurinia Pharmaceuticals Inc. · AUPH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $45.6M | $134M | $176M | $235M | $283M |
| Revenue growth | −9.0% | 193.9% | 31.0% | 34.0% | 20.4% |
| Gross margin | 97.6% | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating margin | −396.3% | −83.2% | −52.2% | −2.0% | 37.1% |
| Net income | −$181M | −$108M | −$78.0M | $5.8M | $287M |
| Net margin | −396.8% | −80.7% | −44.5% | 2.4% | 101.5% |
| Diluted EPS | −$1.40 | −$0.76 | −$0.54 | $0.04 | $2.07 |
| Cash | |||||
| Cash from operations | −$158M | −$79.5M | −$33.5M | $44.4M | $136M |
| Share buybacks | — | $0.0M | $0.0M | $40.2M | $98.2M |
| Share count change | 9.2% | 9.7% | 0.9% | 2.1% | −5.1% |
| Debt and strength | |||||
| Cash and short-term investments | $232M | $94.1M | $48.8M | $83.4M | $80.2M |
| Shareholders' equity | $479M | $405M | $378M | $377M | $581M |
| Current ratio | 12.6x | 9.6x | 5.5x | 4.6x | 5.2x |
| Interest coverage | — | — | −33.0x | −1.0x | 24.2x |
| Returns and quality | |||||
| Return on equity | −40.8% | −24.5% | −19.9% | 1.5% | 59.9% |
| Return on tangible equity | −38.4% | −27.1% | −20.9% | 1.5% | 49.7% |
| Piotroski F-score | 1 | 3 | 3 | 5 | 6 |
| Altman Z'' | 6.8 | 4.5 | −0.2 | 0.8 | 5.2 |
Insiders bought, 12 months
$25.1M
1 insider
Insiders sold, 12 months
$0.5M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aurinia Pharmaceuticals Inc. · AUPH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $17.04 a share, the company is worth $2.3B: 7.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001600620). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.